Jaguar Health (NASDAQ:JAGX) reported that all randomized pediatric patients with microvillus inclusion disease have entered the single-blind extension phase of Napo Pharmaceuticals’ pivotal crossover trial evaluating crofelemer.
AbbVie (NYSE:ABBV) reported positive Phase 3 LUNA trial topline results for atogepant, showing reduced migraine days in women with menstrual migraine.
CAMP4 Therapeutics (NASDAQ:CAMP) received authorization from the UK Medicines and Healthcare products Regulatory Agency to include United Kingdom sites in its planned global Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder.
CervoMed (NASDAQ:CRVO) announced that neflamapimod will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias Annual Meeting in October 2026.
Burning Rock Biotech (NASDAQ:BNR) reported second-quarter 2026 revenue of RMB134.7 million, down 9.3% year over year, with net loss increasing to RMB18.4 million.
Axogen (NASDAQ:AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the FDA-approved NerveTape™ device for sutureless peripheral nerve repair.
Disc Medicine (NASDAQ:IRON) reported initial Phase 2 RESTORE-PV results for DISC-3405, showing reduced phlebotomy requirements and stable hematocrit levels in patients with polycythemia vera.
Tyra Biosciences (NASDAQ:TYRA) reported initial Phase 2 SURF302 results showing oral dabogratinib achieved a 79% overall response rate at the 60 mg once-daily dose in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer.
MannKind (NASDAQ:MNKD) and Rose Pharma entered a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational inhaled GLP-1 therapy for weight management.
IDEAYA Biosciences (NASDAQ:IDYA) dosed the first patient in its Phase 3 OptimUM-11 trial to evaluate darovasertib as a first-in-class adjuvant therapy for primary uveal melanoma.
BridgeBio Pharma (NASDAQ:BBIO) reported exploratory Phase 3 PROPEL 3 data showing 52 weeks of oral infigratinib treatment produced favorable trends versus placebo in children with achondroplasia.
Evotec (NASDAQ:EVO) initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses developed by its Just – Evotec Biologics subsidiary.
